June 2026
The global checkpoint inhibitor biologics CDMO market is growing as demand rises for outsourced biologics development and scalable immuno-oncology manufacturing.
July 2026
Explore the checkpoint inhibitor drugs market, driven by rising cancer prevalence, expanding indications for PD-1/PD-L1 and CTLA-4 inhibitors, and advancements in immuno-oncology therapies.
April 2026
The global immune checkpoint inhibitors market size is predicted to hit around USD 258.91 billion by 2035 from USD 58.53 billion in 2025 with a CAGR of 16.03%.
February 2026
The global biologics CDMO market size was valued at USD 23.08 billion in 2025 and is projected to hit around USD 55.11 billion by 2035 with a healthy CAGR of 9.14%.
July 2026
The global VMAT2 inhibitors market size was evaluated at USD 6.04 billion in 2025 and is predicted to hit around USD 15.29 billion by 2035, growing at a CAGR of 9.74%.
July 2026
The orthobiologics market size was estimated at USD 7.37 billion in 2025 and is expected to surge around USD 12.55 billion by 2035, with a notable CAGR of 5.47%.
July 2026
The oncology CDMO market is expanding rapidly, fueled by rising cancer prevalence, growing demand for advanced therapies like ADCs and cell & gene therapies, and the increasing need for specialized outsourcing services.
July 2026
The global ophthalmic drug CDMO market expands with advancements in drug delivery systems and rising prevalence of chronic eye diseases globally.
July 2026
The high-potency API (HPAPI) CDMO market is expanding with rising demand for oncology drugs, targeted therapies, and advanced containment solutions.
July 2026
The global C5 complement inhibitors market size is estimated to hit around USD 17.83 billion by 2035 increasing from USD 4.85 billion in 2025, with a CAGR of 13.90%.
July 2026
The global oral solid dose oncology CDMO market is growing with rising demand for outsourced cancer drug manufacturing and advanced solid dosage formulation.
June 2026
The rare disease small-batch CDMO market is expanding with demand for specialized manufacturing of orphan drugs and niche therapies.
June 2026
The global small molecule innovator CDMO market size is valued at USD 56.41 billion in 2025 and is projected to hit around USD 103.22 billion by 2035 with a CAGR of 6.23%.
June 2026
The global sterile injectables CDMO market size is estimated to hit around USD 11.82 billion by 2035 from USD 4.73 billion in 2025, with a CAGR of 9.59%.
June 2026
The global SGLT-2 inhibitors market size is estimated to hit around USD 33.11 billion by 2035 increasing from USD 18.18 billion in 2025, with a CAGR of 6.18%.
June 2026
The global pharmaceutical CDMO for formulations market size is accounted to hit around USD 103.33 billion by 2035, increasing from USD 48.85 billion in 2025, with a CAGR of 7.78%.
June 2026
The global leukemia inhibitory factor (LIF) market size is estimated to hit around USD 3.13 billion by 2035 increasing from USD 1.34 billion in 2025, with a CAGR of 8.85%.
June 2026
The global PD-1 inhibitor drugs market size was estimated at USD 48.69 billion in 2025 and is expected to hit around USD 201.87 billion by 2035, growing at a CAGR of 15.28% from 2026 to 2035.
June 2026
The global AI-integrated CDMO process optimization market is growing as contract manufacturers adopt AI to streamline drug development and manufacturing workflows.
June 2026
The global peptide therapeutics CDMO market is growing as pharma and biotech companies outsource complex peptide drug development and manufacturing.
June 2026
The global neurological rare disease biologics market is growing as advanced biologics address unmet needs in rare neurological disorders.
June 2026
The US biologics market size was evaluated at USD 203.60 billion in 2025 and is predicted to hit around USD 525.67 billion by 2035, growing at a CAGR of 9.95 %.
June 2026
The global calcineurin inhibitors market size was evaluated at USD 10.42 billion in 2025 and is predicted to hit around USD 20.88 billion by 2035, growing at a CAGR of 7.20%.
May 2026
Europe Pharmaceutical CDMO market size is projected to hit around USD 94.94 billion by 2035, rising from USD 45.68 billion in 2025, growing at a CAGR of 7.59%.
May 2026
The global active pharmaceutical ingredients CDMO market size is evaluated at USD 116.77 billion in 2025 and is predicted to hit around USD 231.48 billion by 2035, growing at a CAGR of 7.81%.
April 2026
The global chemical drug CDMO market size was evaluated at USD 13.20 billion in 2025 and is predicted to hit around USD 29.84 billion by 2035, growing at a CAGR of 8.50%.
April 2026
The global chemical API CDMO market size was evaluated at USD 16.80 billion in 2025 and is predicted to hit around USD 40.88 billion by 2035, growing at a CAGR of 9.30%.
April 2026
The global mRNA therapeutics CDMO market size is estimated to hit around USD 14.63 billion by 2035 from USD 5.09 billion in 2025, with a CAGR of 11.14%.
April 2026
The global proton pump inhibitors market size is estimated to hit around USD 7.33 billion by 2035 increasing from USD 4.29 billion in 2025, with a CAGR of 5.50%.
March 2026
The global cancer biologics market size was valued at USD 117.45 billion in 2025 and is expected to hit around USD 235.81 billion by 2035 with a CAGR of 7.22%.
+1 650 460 3308
+61 485 981 310 +91 87933 22019
sales@precedenceresearch.com